Division of Cardiac Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, Virginia.
Division of Cardiac Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, Virginia.
Ann Thorac Surg. 2022 Oct;114(4):e273-e274. doi: 10.1016/j.athoracsur.2021.12.015. Epub 2022 Jan 6.
The Lotus (Boston Scientific) valve stood out from alternative transcatheter aortic valve replacement (TAVR) valves because of its ability to recapture and redeploy if initial placement was unsatisfactory. With the exponential rise in TAVR, there have been numerous reports of TAVR valve explantation. A 79-year-old man with nonrheumatic aortic valve stenosis who had undergone TAVR with a Lotus valve 12 months earlier presented for surgical excision for early valve failure. The Food and Drug Administration stated that already implanted Lotus valves are not a safety issue; however, cases of valve degeneration will occur, necessitating future valve explantation.
波士顿科学公司的 Lotus 瓣膜因其能够在初始放置不满意时重新捕获和重新部署而从其他经导管主动脉瓣置换 (TAVR) 瓣膜中脱颖而出。随着 TAVR 的指数级增长,已经有大量 TAVR 瓣膜取出的报告。一名 79 岁的男性,患有非风湿性主动脉瓣狭窄,在 12 个月前接受了 Lotus 瓣膜的 TAVR,因早期瓣膜失效而进行手术切除。美国食品和药物管理局表示,已经植入的 Lotus 瓣膜不是安全问题;然而,瓣膜退化的情况将会发生,需要未来进行瓣膜取出。